Browsing: FDA Breakthrough Therapy Designation

Spruce Biosciences has received FDA Breakthrough Therapy Designation for Tralesinidase Alfa (TA-ERT), an enzyme replacement therapy targeting Sanfilippo Syndrome Type B (MPS IIIB), advancing treatment prospects for this rare disorder.